Czech biotech firm SOTIO, part of the privately-owned PPF Group, has completed the acquisition of Cytune Pharma, a firm developing inrterleukin (IL)-15 based therapies for the treatment of cancer, for an undisclosed sume
SOTIO will continue development of lead program SO-C101 (RLI-15) and intends to initiate first-in-human clinical trials in early 2019. All Cytune projects will be developed as part of SOTIO’s pipeline.
Following the completion of the deal, which was announced in 2015, Cytune is to become an important part of SOTIO’s activities in the biotech sector, and will closely collaborate with its affiliate Accord Research.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze